Uber stock surges after Nvidia partnership announcement
Investing.com -- Getinge reported strong third-quarter results that exceeded analyst expectations, driving its shares up 3.6% in early Stockholm trading on Tuesday.
The company posted organic order growth of 4.7% in Q3, while sales increased by 9.5% organically. Adjusted EBITA rose 20% in reported terms, coming in 5.8% above street expectations.
Sales for the quarter exceeded analyst consensus by 2.4%, with particularly strong performance in the Acute Care Therapies (ACT) division, which saw 11.4% organic sales growth. The Life Sciences segment delivered even stronger results with 15.9% organic growth, while Surgical Workflows increased by 4.7%.
The company achieved these results despite facing SEK236 million in headwinds from currencies and tariffs during the quarter, compared to SEK270 million in headwinds during Q2.
In the key high-margin ACT division, orders increased 6.5% organically, driven by ventilator demand as smaller competitors exited the market. The company also noted strong demand for ECLS consumables. Life Science orders surged 22% organically in Q3, offsetting earlier weakness.
Getinge’s adjusted gross margin improved by 90 basis points in Q3, supported by increased volume and favorable product mix.
Despite the strong performance through the first nine months of the year, with 6.6% organic sales growth, Getinge maintained its full-year 2025 outlook of 2-5% organic sales growth. The company cited tough fourth-quarter comparisons as the reason for not raising guidance.
The fourth quarter historically represents Getinge’s most significant period, having contributed 44% to the company’s full-year 2024 adjusted EBITA.
For its mid-term outlook, established in May 2024, Getinge targets 3-6% sales CAGR over 2024-28 (from a 2023 base), with adjusted EBITA margin expected to reach 16-19% by the end of that period. Adjusted EPS growth is projected at more than 12%.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.